SynthesisThe Cochrane database of systematic reviews2017

Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.

Jian Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.